These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 37075696)

  • 21. Unmet Need for Further LDL-C Lowering in India despite Statin Therapy: Lipid Association of India Recommendations for the Use of Bempedoic Acid.
    Mehta V; Puri R; Duell PB; Iyengar SS; Wong ND; Yusuf J; Mukhopadhyay S; Pradhan A; Muruganathan A; Wangnoo SK; Kapoor D; Rastogi A; Tiwaskar MH; Mahajan K; Narasingan SN; Agarwala R; Bordoloi N; Soumitra K; Chakraborty R; Shetty S; Saboo B; Khan A; Prabhakar D; Khanna NN; Mehta A; Bansal M; Kasliwal R; Mehrotra R; Chag M; Sheikh A; Sattur GB; Manoria PC; Pareek KK; Pancholia AK; Melinker RP; Nanda R; Kalra D
    J Assoc Physicians India; 2022 Sep; 70(9):11-12. PubMed ID: 36082889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial.
    Ridker PM; Lei L; Ray KK; Ballantyne CM; Bradwin G; Rifai N
    J Clin Lipidol; 2023; 17(2):297-302. PubMed ID: 36813656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bempedoic Acid: a cholesterol lowering agent with a novel mechanism of action.
    Nguyen H; Akamnonu I; Yang T
    Expert Rev Clin Pharmacol; 2021 May; 14(5):545-551. PubMed ID: 33691561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bempedoic acid: a promising novel agent for LDL-C lowering.
    Agarwala A; Goldberg AC
    Future Cardiol; 2020 Sep; 16(5):361-371. PubMed ID: 32463301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial.
    Lalwani ND; Hanselman JC; MacDougall DE; Sterling LR; Cramer CT
    J Clin Lipidol; 2019; 13(4):568-579. PubMed ID: 31202641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Network Meta-Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid-Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low-Density Lipoprotein Cholesterol.
    Toth PP; Bray S; Villa G; Palagashvili T; Sattar N; Stroes ESG; Worth GM
    J Am Heart Assoc; 2022 Sep; 11(18):e025551. PubMed ID: 36073669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
    Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bempedoic acid: Review of a novel therapy in lipid management.
    Delevry D; Gupta EK
    Am J Health Syst Pharm; 2021 Jan; 78(2):95-104. PubMed ID: 33399194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial.
    Rubino J; MacDougall DE; Sterling LR; Hanselman JC; Nicholls SJ
    Atherosclerosis; 2021 Mar; 320():122-128. PubMed ID: 33514449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world utilization of bempedoic acid in an academic preventive cardiology practice.
    Warden BA; Cardiology BA; Purnell JQ; Duell PB; Fazio S
    J Clin Lipidol; 2022; 16(1):94-103. PubMed ID: 34924351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study).
    Ballantyne CM; Banach M; Bays HE; Catapano AL; Laufs U; Stroes ESG; Robinson P; Lei L; Ray KK
    Am J Cardiol; 2022 Jul; 174():1-11. PubMed ID: 35483979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials.
    Zhao X; Ma X; Luo X; Shi Z; Deng Z; Jin Y; Xiao Z; Tan L; Liu P; Jiang S; Shu Y; Tang B; Qiu C
    BMC Pharmacol Toxicol; 2020 Dec; 21(1):86. PubMed ID: 33276805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bempedoic Acid: for Whom and When.
    Ruscica M; Sirtori CR; Carugo S; Banach M; Corsini A
    Curr Atheroscler Rep; 2022 Oct; 24(10):791-801. PubMed ID: 35900636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How Will Our Practice Change After the CLEAR Outcomes Trial?
    Abrahams T; Nelson AJ; Nicholls SJ
    Curr Atheroscler Rep; 2024 Mar; 26(3):83-89. PubMed ID: 38294660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance.
    Bays HE; Bloedon LT; Lin G; Powell HA; Louie MJ; Nicholls SJ; Lincoff AM; Nissen SE
    J Clin Lipidol; 2024; 18(1):e59-e69. PubMed ID: 37951797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis.
    Cicero AFG; Fogacci F; Hernandez AV; Banach M;
    PLoS Med; 2020 Jul; 17(7):e1003121. PubMed ID: 32673317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance.
    Susekov AV; Korol LA; Watts GF
    Cardiovasc Drugs Ther; 2021 Aug; 35(4):841-852. PubMed ID: 33502687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Add-on ezetimibe treatment to low-dose statins vs medium-intensity statin monotherapy in coronary artery disease patients with poorly controlled dyslipidemia.
    Sakuma M; Toyoda S; Hashimoto R; Yazawa H; Masuyama T; Hirose S; Waku R; Hasumi H; Numao T; Abe S; Inoue T
    Hypertens Res; 2019 Dec; 42(12):1923-1931. PubMed ID: 31409915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia.
    Cicero AFG; Fogacci F; Cincione I
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1031-1038. PubMed ID: 34197267
    [No Abstract]   [Full Text] [Related]  

  • 40. ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials.
    Ruscica M; Banach M; Sahebkar A; Corsini A; Sirtori CR
    Expert Opin Pharmacother; 2019 May; 20(7):791-803. PubMed ID: 30810432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.